title: Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
abstract: We conducted a Phase I open-label trial of 2',3'-dideoxyinosine (ddI) for the treatment of the acquired immunodeficiency syndrome (AIDS) and severe AIDS-related complex. A single daily dose of ddI was administered orally to 34 patients (17 with AIDS and 17 with AIDS-related complex) for a median of 12 weeks (range, 2 to 56). We studied six dose levels from 1.6 to 30.4 mg per kilogram of body weight per day. Of the 17 patients previously treated with zidovudine, 13 had had hematologic side effects. The maximal tolerated dose of oral ddI was estimated to be 20.4 mg per kilogram per day. Pancreatitis and peripheral neuropathy were the major dose-limiting toxic effects. Other toxic effects included elevations in hepatic transaminase levels, abnormalities in cardiac conduction, rash, and asymptomatic elevations in serum urate levels and the creatine kinase fraction from skeletal muscle. Treatment with ddI was associated with an increase in the mean number of CD4 lymphocytes from 125 per cubic millimeter at base line to 182 per cubic millimeter after 10 weeks (P = 0.005). There were also increases after 12 weeks in the mean total lymphocyte count (from 0.8 to 1.2 x 10(9) per liter) and the mean hemoglobin level (from 12.9 to 14.1 g per deciliter) (both P less than 0.01). The amount of human immunodeficiency virus p24 antigen decreased by more than 50 percent in 14 of 19 patients with detectable antigen. No differences in response were observed between patients previously treated with zidovudine and those never treated with the drug. We conclude that ddI has antiretroviral activity in patients with AIDS or AIDS-related complex and that the toxicity of ddI differs from that of zidovudine. However, controlled trials are necessary to evaluate the efficacy of ddI.
authors: Department of Medicine, Boston City Hospital, MA 02118.
authors: T P
authors: TP
authors: Cooley
authors: L M
authors: LM
authors: Kunches
authors: C A
authors: CA
authors: Saunders
authors: J K
authors: JK
authors: Ritter
authors: C J
authors: CJ
authors: Perkins
authors: C
authors: C
authors: McLaren
authors: R P
authors: RP
authors: McCaffrey
authors: H A
authors: HA
authors: Liebman
mesh_terms: D000386:AIDS-Related Complex / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D015488:HIV Antigens / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D006377:T-Lymphocytes, Helper-Inducer; D050378:T-Lymphocytes, Regulatory
chemical_list: D015488:HIV Antigens; D016049:Didanosine